Enhanced Pet Sciences is pleased to announce the completion and publishing of the final phases of its CBD canine studies, a multi-year clinical trial demonstrating safety, dosing, the absence of immune response or contraindication to vaccines, and efficacy in the areas of anti-inflammation, anti-itching, insulin (diabetic) regulation, microbiome support, anti-fungal and anti-oxidative functions, all under agreement with the University of Kentucky’s Food and Animal Sciences Department. The final phases of these canine studies can be found for a limited time at the under-construction website: https://epscpets.com/our-research/
Dr. David Harmon of the University of Kentucky’s Food and Animal Sciences Department states “Beyond the safety aspects demonstrated in earlier trials, these latest studies demonstrate various beneficial increases and decreases in canine metabolic and sub-metabolic activity after 3 weeks of using Enhanced Pet Sciences’ CBD Pet Chews at dosing of 4.5mg of CBD per kg of body weight.”
EPS points to the following key takeaways from this latest publication:
- Several metabolites were identified as potential biomarkers for changes in the canine metabolome by CBD that point to the reduction of inflammation.
- The up-regulation and down-regulation of several key metabolites were identified which point to pathways by which CBD can exert suspected anti-inflammatory, antioxidant, anti-obesity and anti-diabetic effects.
- Such up-regulation and down-regulation of metabolites that point to potential for CBD to influence lipid, carbohydrate, amino acid, vitamin, and nucleotide metabolism in the body as well as benefits to the gut microbiome such as the promotion of beneficial bacteria and gut health.
- Decrease in biomarkers related to fungal infection.
- Other plant phytonutrient metabolites with anti-inflammatory, anti-bacterial, and wound healing properties.
Reid Parr, Director of Research at EPSC is pleased with the completion of this muti-year study stating: “The first phases of our canine studies validated safety, dosing, palatability and an indication of anti-itching function. The second phases validated the use of CBD without immune response or contraindication to vaccines. These final phases have validated not only the indication of anti-inflammatory functions that we suspected by way of the results we’ve seen on our equine studies, but also some of the different mechanisms in the body by which these various desired effects are taking place. I am very pleased to see that our unique formulation of CBD infused pet chews can produce these helpful results, that they have not shown to do any harm, and that we can now move forward with our regulatory indication applications with the aim of making them widely available across global mass-market retail networks.”
Michael French, President of EPSC added, “Pet Parents love their pets and must be their advocate, trust is key. We have seen a lot of mystery in the CBD space without any credible history, we chose a different path. With the completion of these trials, EPSC has taken a huge step towards earning the trust of pet parents.”
About Enhanced Pet Sciences Corp.
The company is truly vertically integrated with indoor and outdoor farming, agricultural processing, extraction of CBD and other key ingredients, and the manufacturing of consumer-packaged goods.
In 2017, a master agreement was signed with the University of Kentucky. We believe the multi-year studies has proven helpful to researchers, regulators, and the general public to better understand the effects of hemp derived products.
The company is based in Bourbon County, Kentucky. The 500,000 square foot greenhouse and ag processing center allows for premium growing and production year-round. Its new Extraction and Manufacturing Center allows for extraction, formulation, and consumer packaged goods manufacturing in a custom-built environment.
For more information contact:
Michael Joseph French
President
btlmedia@shaw.ca
Or visit:
https://epscpets.com/contact-us/
Safe Harbor
Certain statements herein relating to the Company constitute “forward-looking statements” within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward-looking statements.” Such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and/or sales of hemp derived products, quantities of future hemp products production, anticipated revenues in connection with such sales, the overall projected size of the market, completion and/or expansion of production facilities, and other information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. Actual results may differ materially from those expressed or implied by such forward-looking statements and involve risk and uncertainties relating to the Company’s historical experience with regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in hemp products prices, actual operating performance of facilities, and other uninsured risks. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Contents are provided for general information purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. The information in this news release is qualified in its entirety.